Of course, the main question remains the free cash flow we can expect going forward.
Some elements of answer :
- the company does not expect major change for margin in FY 25, while its revenue could increase given the level of its order book,
- performance rights awarded in FY 24 will be partly exercised if the compound annual growth* of NPAT is at least 5 % (performance rights will be fully exercised if annual growth is 12 %).
* between FY 24 and FY 26.
- Forums
- ASX - By Stock
- Probably worth more attention
Of course, the main question remains the free cash flow we can...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SHA (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.78 |
Change
0.060(2.21%) |
Mkt cap ! $232.1M |
Open | High | Low | Value | Volume |
$2.72 | $2.78 | $2.72 | $2.652K | 960 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 82 | $2.76 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.78 | 1478 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 82 | 2.760 |
2 | 3249 | 2.740 |
1 | 5968 | 2.730 |
1 | 9160 | 2.720 |
3 | 2629 | 2.700 |
Price($) | Vol. | No. |
---|---|---|
2.780 | 1478 | 2 |
2.800 | 2000 | 1 |
2.810 | 3401 | 1 |
2.820 | 3000 | 1 |
2.830 | 1793 | 1 |
Last trade - 12.13pm 12/11/2024 (20 minute delay) ? |
Featured News
SHA (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online